Lab Members

Marcela Haro, PhD

Postdoctoral Fellow Email: marcela.haro@cshs.org

Learn More

Marcela Haro, PhD, earned her doctoral degree from Wake Forest University. As a graduate student, she trained with Karen Haas, PhD, where her research focused on the mechanisms regulating B cell responses to tumor associated carbohydrate antigens. She is interested in the roles of B cells in ovarian cancer progression and the influence of cancer associated fibroblasts in the anti-tumor B cell response.

Ye Hu, PhD

Postdoctoral Fellow Email: ye.hu@cshs.org

Learn More

Ye Hu, MD, PhD, earned her doctoral and medical degrees from Shanghai Jiao Tong University School of Medicine, China. As a graduate student, she trained with Jingyuan Fang, MD, PhD, where her research focused on the development and progression of gastrointestinal tumors. After finishing her residency, Hu joined the Orsulic Laboratory. She is interested in the role of cancer-associated fibroblasts in shaping the immune composition of tumors and their potential as a therapeutic target.

Dongyu Jia, PhD

Postdoctoral Fellow Email: dongyu.jia@cshs.org

Learn More

Dongyu Jia, PhD, earned his doctoral degree in cellular and molecular biology from Florida State University. He trained in the laboratory of Wu-Min Deng, PhD, where he gained extensive experience in cellular and molecular biology, genetics, and developmental biology. He is interested in the role of COL11A1 in stromal activation and ovarian cancer progression.

Barbie Taylor-Harding, PhD

Research Associate Email: barbie.taylor-harding@cshs.org

Learn More

Barbie Taylor-Harding, PhD, earned her doctoral degree in molecular biology from the University of London, UK. She trained with Nicholas Dyson, PhD, at Massachusetts General Hospital Cancer Center and Harvard Medical School, where her research focused on the molecular mechanisms underlying cancer development. She currently performs managerial duties within the Women’s Cancer Program and works in the Orsulic Laboratory, where her research interests focus on improving therapeutic efficacy and identifying predictive markers of clinical outcomes in ovarian cancer.